{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:19:42Z","timestamp":1788981582539,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13318-026-01020-2","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:48:03Z","timestamp":1782928083000},"page":"625-636","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetic Modeling Study of Glibenclamide in Chinese Healthy Volunteers"],"prefix":"10.1007","volume":"51","author":[{"given":"Yaou","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2583-8080","authenticated-orcid":false,"given":"Tianyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocong","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"1020_CR1","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1007\/s00125-021-05571-8","volume":"64","author":"A Green","year":"2021","unstructured":"Green A, Hede SM, Patterson CC, Wild SH, Imperatore G, Roglic G, et\u00a0al. Type 1 diabetes in 2017: global estimates of incident and prevalent cases in children and adults. Diabetologia. 2021;64:2741\u201350. https:\/\/doi.org\/10.1007\/s00125-021-05571-8.","journal-title":"Diabetologia"},{"key":"1020_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1058828","volume":"11","author":"AM Salinas Mart\u00ednez","year":"2023","unstructured":"Salinas Mart\u00ednez AM, Ju\u00e1rez Montes AG, Ram\u00edrez Morado Y, Cordero Franco HF, Guzm\u00e1n de la Garza FJ, Hern\u00e1ndez Oyervides LC, et\u00a0al. Idealistic, realistic, and unrealistic expectations of pharmacological treatment in persons with type 2 diabetes in primary care. Front Public Health. 2023;11:1058828. https:\/\/doi.org\/10.3389\/fpubh.2023.1058828.","journal-title":"Front Public Health"},{"key":"1020_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/CPAA.S54809","volume":"6","author":"V Rambiritch","year":"2014","unstructured":"Rambiritch V, Maharaj B, Naidoo P. Glibenclamide in patients with poorly controlled type 2 diabetes: a 12-week, prospective, single-center, open-label, dose-escalation study. Clin Pharmacol Adv Appl. 2014;6:63\u20139. https:\/\/doi.org\/10.2147\/CPAA.S54809.","journal-title":"Clin Pharmacol Adv Appl"},{"key":"1020_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0168-8227(91)90098-x","volume":"11","author":"N Takeda","year":"1991","unstructured":"Takeda N, Horiya T, Yasuda K, Goto S, Hayashi M, Aoyama K, et\u00a0al. Comparative effects of diet or glibenclamide on insulin secretion and action in non-obese NIDDM. Diabetes Res Clin Pract. 1991;11:99\u2013106. https:\/\/doi.org\/10.1016\/0168-8227(91)90098-x.","journal-title":"Diabetes Res Clin Pract"},{"key":"1020_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ctim.2015.11.005","volume":"24","author":"Y Hu","year":"2016","unstructured":"Hu Y, Zhou X, Liu P, Wang B, Duan D-M, Guo D-H. A comparison study of metformin only therapy and metformin combined with Chinese medicine jianyutangkang therapy in patients with type 2 diabetes: a randomized placebo-controlled double-blind study. Complement Ther Med. 2016;24:13\u20138. https:\/\/doi.org\/10.1016\/j.ctim.2015.11.005.","journal-title":"Complement Ther Med"},{"key":"1020_CR6","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/pedi.12823","volume":"20","author":"J Beltrand","year":"2019","unstructured":"Beltrand J, Baptiste A, Busiah K, Bouazza N, Godot C, Boucheron A, et\u00a0al. Glibenclamide oral suspension: suitable and effective in patients with neonatal diabetes. Pediatr Diabetes. 2019;20:246\u201354. https:\/\/doi.org\/10.1111\/pedi.12823.","journal-title":"Pediatr Diabetes"},{"key":"1020_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s005920050081","volume":"34","author":"L Luzi","year":"1997","unstructured":"Luzi L, Pozza G. Glibenclamide: an old drug with a novel mechanism of action? Acta Diabetol. 1997;34:239\u201344. https:\/\/doi.org\/10.1007\/s005920050081.","journal-title":"Acta Diabetol"},{"key":"1020_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197634","volume":"13","author":"P Proks","year":"2018","unstructured":"Proks P, Kramer H, Haythorne E, Ashcroft FM. Binding of sulphonylureas to plasma proteins\u2014A KATP channel perspective. PLoS ONE. 2018;13:e0197634. https:\/\/doi.org\/10.1371\/journal.pone.0197634.","journal-title":"PLoS ONE"},{"key":"1020_CR9","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1007\/s00125-008-1026-8","volume":"51","author":"Q Wang","year":"2008","unstructured":"Wang Q, Heimberg H, Pipeleers D, Ling Z. Glibenclamide activates translation in rat pancreatic beta cells through calcium-dependent mTOR, PKA and MEK signalling pathways. Diabetologia. 2008;51:1202\u201312. https:\/\/doi.org\/10.1007\/s00125-008-1026-8.","journal-title":"Diabetologia"},{"key":"1020_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113469","volume":"143","author":"AA Aboushouk","year":"2024","unstructured":"Aboushouk AA, Saad HM, Rohiem AH, Gad El-Karim DRS. New Insights on the potential therapeutic effects of glibenclamide and obeticholic acid against alloxan-induced diabetes mellitus in rat model. Int Immunopharmacol. 2024;143:113469. https:\/\/doi.org\/10.1016\/j.intimp.2024.113469.","journal-title":"Int Immunopharmacol"},{"key":"1020_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/BF00265847","volume":"40","author":"H Mulder","year":"1991","unstructured":"Mulder H, Schopman W, van der Lely AJ. Extrapancreatic insulin effect of glibenclamide. Eur J Clin Pharmacol. 1991;40:379\u201381. https:\/\/doi.org\/10.1007\/BF00265847.","journal-title":"Eur J Clin Pharmacol"},{"key":"1020_CR12","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1067\/mcp.2002.122476","volume":"71","author":"J Kirchheiner","year":"2002","unstructured":"Kirchheiner J, Brockm\u00f6ller J, Meineke I, Bauer S, Rohde W, Meisel C, et\u00a0al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther. 2002;71:286\u201396. https:\/\/doi.org\/10.1067\/mcp.2002.122476.","journal-title":"Clin Pharmacol Ther"},{"key":"1020_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/CPAA.S102676","volume":"8","author":"V Rambiritch","year":"2016","unstructured":"Rambiritch V, Naidoo P, Maharaj B, Pillai G. Population pharmacokinetic modeling of glibenclamide in poorly controlled South African type 2 diabetic subjects. Clin Pharmacol Adv Appl. 2016;8:83\u201392. https:\/\/doi.org\/10.2147\/CPAA.S102676.","journal-title":"Clin Pharmacol Adv Appl"},{"key":"1020_CR14","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1517\/14656566.2012.738196","volume":"13","author":"EM Lamos","year":"2012","unstructured":"Lamos EM, Stein SA, Davis SN. Combination of glibenclamide-metformin HCl for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother. 2012;13:2545\u201354. https:\/\/doi.org\/10.1517\/14656566.2012.738196.","journal-title":"Expert Opin Pharmacother"},{"key":"1020_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.824232","volume":"13","author":"C Chaoyang","year":"2022","unstructured":"Chaoyang C, Xiu D, Ran W, Lingyun M, Simiao Z, Ruoming L, et\u00a0al. Pharmacokinetic characteristics of siponimod in healthy volunteers and patients with multiple sclerosis: analyses of published clinical trials. Front Pharmacol. 2022;13:824232. https:\/\/doi.org\/10.3389\/fphar.2022.824232.","journal-title":"Front Pharmacol"},{"key":"1020_CR16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/cpdd.1219","volume":"12","author":"X Huang","year":"2023","unstructured":"Huang X, Huang J, Li X, Chen L. Pharmacokinetic and bioequivalence studies of 2 metformin glibenclamide tablets in healthy Chinese subjects under fasting and fed conditions. Clin Pharmacol Drug Dev. 2023;12:509\u201317. https:\/\/doi.org\/10.1002\/cpdd.1219.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1020_CR17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00003088-200039060-00001","volume":"39","author":"PJ Williams","year":"2000","unstructured":"Williams PJ, Ette EI. The role of population pharmacokinetics in drug development in light of the Food and Drug Administration\u2019s \u201cGuidance for Industry: population pharmacokinetics.\u201d Clin Pharmacokinet. 2000;39:385\u201395. https:\/\/doi.org\/10.2165\/00003088-200039060-00001.","journal-title":"Clin Pharmacokinet"},{"key":"1020_CR18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2165\/00003088-199631020-00007","volume":"31","author":"HJ Koch","year":"1996","unstructured":"Koch HJ. Population methods in drug development and related fields. Clin Pharmacokinet. 1996;31:164. https:\/\/doi.org\/10.2165\/00003088-199631020-00007.","journal-title":"Clin Pharmacokinet"},{"key":"1020_CR19","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s0021663560352","volume":"356","author":"F Susanto","year":"1996","unstructured":"Susanto F, Reinauer H. Glibenclamide in serum: comparison of high-performance liquid chromatography using fluorescence detector and liquid chromatography\/mass spectrometry with atmospheric-pressure chemical-ionization (APCI LC\/MS). Anal Bioanal Chem. 1996;356:352\u20137. https:\/\/doi.org\/10.1007\/s0021663560352.","journal-title":"Anal Bioanal Chem"},{"key":"1020_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.12793\/tcp.2017.25.3.125","volume":"25","author":"W-S Park","year":"2017","unstructured":"Park W-S. Pharmacometric models simulation using NONMEM, Berkeley Madonna and R. Transl Clin Pharmacol. 2017;25:125\u201333. https:\/\/doi.org\/10.12793\/tcp.2017.25.3.125.","journal-title":"Transl Clin Pharmacol"},{"key":"1020_CR21","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s11095-007-9361-x","volume":"24","author":"AC Hooker","year":"2007","unstructured":"Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res. 2007;24:2187\u201397. https:\/\/doi.org\/10.1007\/s11095-007-9361-x.","journal-title":"Pharm Res"},{"key":"1020_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/0091270010390040","volume":"52","author":"DD Wang","year":"2012","unstructured":"Wang DD, Zhang S. Standardized visual predictive check versus visual predictive check for model evaluation. J Clin Pharmacol. 2012;52:39\u201354. https:\/\/doi.org\/10.1177\/0091270010390040.","journal-title":"J Clin Pharmacol"},{"key":"1020_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/s0304-4076(97)86571-2","volume":"81","author":"PL Gozalo","year":"1997","unstructured":"Gozalo PL. Nonparametric bootstrap analysis with applications to demographic effects in demand functions. J Econom. 1997;81:357\u201393. https:\/\/doi.org\/10.1016\/s0304-4076(97)86571-2.","journal-title":"J Econom"},{"issue":"3","key":"1020_CR24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00001648-199205000-00015","volume":"3","author":"S Greenland","year":"1992","unstructured":"Greenland S. The bookstrap method for standard errors and confidence intervals of the adjusted attributable risk. Epidemiology. 1992;3(3):271. https:\/\/doi.org\/10.1097\/00001648-199205000-00015.","journal-title":"Epidemiology"},{"key":"1020_CR25","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s002280050004","volume":"55","author":"A J\u00f6nsson","year":"2000","unstructured":"J\u00f6nsson A, Chan JC, Rydberg T, Vaaler S, Hallengren B, Cockram CS, et\u00a0al. Pharmacodynamics and pharmacokinetics of intravenous glibenclamide in Caucasian and Chinese patients with type-2 diabetes. Eur J Clin Pharmacol. 2000;55:721\u20137. https:\/\/doi.org\/10.1007\/s002280050004.","journal-title":"Eur J Clin Pharmacol"},{"key":"1020_CR26","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1177\/106002809603000507","volume":"30","author":"LA Jaber","year":"1996","unstructured":"Jaber LA, Antal EJ, Welshman IR. Pharmacokinetics and pharmacodynamics of glyburide in young and elderly patients with non-insulin-dependent diabetes mellitus. Ann Pharmacother. 1996;30:472\u20135. https:\/\/doi.org\/10.1177\/106002809603000507.","journal-title":"Ann Pharmacother"},{"key":"1020_CR27","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/j.1365-2125.1990.tb03688.x","volume":"29","author":"SW Coppack","year":"1990","unstructured":"Coppack SW, Lant AF, McIntosh CS, Rodgers AV. Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus. Br J Clin Pharmacol. 1990;29:673\u201384. https:\/\/doi.org\/10.1111\/j.1365-2125.1990.tb03688.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1020_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s0002-9343(85)80010-3","volume":"79","author":"JG Pearson","year":"1985","unstructured":"Pearson JG. Pharmacokinetics of glyburide. Am J Med. 1985;79:67\u201371. https:\/\/doi.org\/10.1016\/s0002-9343(85)80010-3.","journal-title":"Am J Med"},{"key":"1020_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/j.1875-9114.1998.tb03826.x","volume":"18","author":"WG Tracewell","year":"1998","unstructured":"Tracewell WG, Stalker DJ, Maloley PA, Gallagher TF, Gwilt PR. Population pharmacokinetics of glyburide in patients with well-controlled diabetes. Pharmacotherapy. 1998;18:51\u20136. https:\/\/doi.org\/10.1002\/j.1875-9114.1998.tb03826.x.","journal-title":"Pharmacotherapy"},{"key":"1020_CR30","first-page":"532","volume":"10","author":"TL Schwinghammer","year":"1991","unstructured":"Schwinghammer TL, Antal EJ, Kubacka RT, Hackimer ME, Johnston JM. Pharmacokinetics and pharmacodynamics of glyburide in young and elderly nondiabetic adults. Clin Pharm. 1991;10:532\u20138.","journal-title":"Clin Pharm"},{"key":"1020_CR31","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/j.1365-2125.2006.02836.x","volume":"63","author":"JJ Lilja","year":"2007","unstructured":"Lilja JJ, Niemi M, Fredrikson H, Neuvonen PJ. Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br J Clin Pharmacol. 2007;63:732\u201340. https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02836.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1020_CR32","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/BF00315518","volume":"45","author":"LA Jaber","year":"1993","unstructured":"Jaber LA, Antal EJ, Slaughter RL, Welshman IR. The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics. Eur J Clin Pharmacol. 1993;45:459\u201363. https:\/\/doi.org\/10.1007\/BF00315518.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01020-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-01020-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01020-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:56:25Z","timestamp":1788980185000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-026-01020-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1020"],"URL":"https:\/\/doi.org\/10.1007\/s13318-026-01020-2","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"21 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Peking University (Clinical trial number:2021-0011) and carried out under the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Owing to the nature of a clinical trial study, the acquisition of written informed consent to participate in the study and publication of the data from patients was beyond feasibility.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no identifying information on any patient in this manuscript.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets used for model development and\/or evaluation, including PopPK model files are available from the corresponding author upon reasonable request.","order":5,"name":"Ethics","label":"Availability of Data and Materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The model codes that support the findings of this study are available upon reasonable request.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yimin Cui, Xiaocong Pang, and Tianyan Zhou made major contribution to the conception of the study. Yaou Liu and Xinhua Cui gathered data in assistance of Ran Xie. Yaou Liu analyzed the data and developed the population pharmacokinetic model. Yaou Liu wrote the manuscript and revised it in consultation with Qingyu Yao and under supervision from Tianyan Zhou. All authors read and approved the final manuscript.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}